TY - JOUR
T1 - Tumor banks and complex data management
T2 - Current and future challenges
AU - Hofman, Paul
AU - Dagher, Georges
AU - Laurent-Puig, Pierre
AU - Marquette, Charles Hugo
AU - Barlesi, Fabrice
AU - Bibeau, Frédéric
AU - Clément, Bruno
N1 - Publisher Copyright:
© 2019 Elsevier Masson SAS
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Tumor banks are asked to clinical and translationnal research project development in oncology. They strongly participate to the assessment, then to the validation of diagnostic, prognostic and predictive biomarkers. The progressive change of these structures leads to induce a professionalization of their functioning and to identify them as key actors in oncology by the stakeholders of the public and private worlds. The progresses made in biotechnologies and therapeutics are rapidly modifying the impact and the proper functioning of the biobanks. These latter are now facing different challenges, in particular for their sustainability. Among the major issues, the integration of the clinical and biological data becoming increasingly complex leads to urgently consider an optimization of the role of different biobanks in France. Their goal is to be an attractive counterpart face to the international competition. The purpose of this review is to briefly describe the current evolution of the biobanks, then their present and future challenges, and finally the role made by the pathologists in these new issues in oncology field.
AB - Tumor banks are asked to clinical and translationnal research project development in oncology. They strongly participate to the assessment, then to the validation of diagnostic, prognostic and predictive biomarkers. The progressive change of these structures leads to induce a professionalization of their functioning and to identify them as key actors in oncology by the stakeholders of the public and private worlds. The progresses made in biotechnologies and therapeutics are rapidly modifying the impact and the proper functioning of the biobanks. These latter are now facing different challenges, in particular for their sustainability. Among the major issues, the integration of the clinical and biological data becoming increasingly complex leads to urgently consider an optimization of the role of different biobanks in France. Their goal is to be an attractive counterpart face to the international competition. The purpose of this review is to briefly describe the current evolution of the biobanks, then their present and future challenges, and finally the role made by the pathologists in these new issues in oncology field.
KW - Big data
KW - Biobanks
KW - Challenges
KW - Oncology
UR - http://www.scopus.com/inward/record.url?scp=85061939605&partnerID=8YFLogxK
U2 - 10.1016/j.annpat.2019.01.017
DO - 10.1016/j.annpat.2019.01.017
M3 - Short survey
C2 - 30819623
AN - SCOPUS:85061939605
SN - 0242-6498
VL - 39
SP - 137
EP - 143
JO - Annales de Pathologie
JF - Annales de Pathologie
IS - 2
ER -